Tissue Diagnostics Market size is estimated to reach $5.54bn by 2025, growing at a CAGR of 6.2% during the forecast period 2020-2025. Tissue diagnostics is the process of removing or treating tissue in the patient for diseases like cancer. Tissue diagnostics help to find the cause of disease and will help in treating the disease at the initial stages. So, it can be analyzed and evaluated under the microscope further for the treatment. An Increase in the adaption of the automated tissue diagnostics for the diagnosis of diseases like cancer, increase in health care investments and rise in the cancer population, are some of the factors that are boosting the market during the forecast period 2020-2025.
By Technology – Segment Analysis
The global Tissue Diagnostics Market based on Technology has Immunohistochemistry (IHC), In Situ Hybridization (ISH), Digital Pathology and Work-flow Management, Special Staining. The Immunohistochemistry (IHC) segment registers for the highest market share in 2019 and is set to continue for the forecast period 2020-2025. The segment is set to emerge owing to the increased usage of this technology and increasing chronic diseases. Digital pathology is also set to have growth owing to the increase in the adaption of the whole sliding among the pathologists. The rise in investment and increased development of new technology is driving the market in the digital pathology and workflow management segment.
Request for Sample of the Report @ https://www.industryarc.com/pdfdownload.php?id=16833
Report Price: $ 4500 (Single User License)
By Application – Segment Analysis
The Application segment of the Tissue Diagnostics Market has Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Prostate Cancer and Other. The Breast Cancer segment registers for the highest market share in 2019 and is set to continue for the forecast period 2020-2025, owning to the increased patients with breast cancer globally. Advancement in genomic technology has been boosting the growth of the prostate cancer market. The discovery of biomarkers and improvement in tissue diagnostic are fueling the market during the forecast period 2020-2025. The funding by the key players in the major countries to treat the chronic diseases over worldwide is supporting the growth of the market.
By Geography – Segment Analysis
Based on geography the global Tissue Diagnostics Market is segmented into North America, Europe, Asia-Pacific and Rest of the World. North America region has dominated the market in the year 2019 and is set to have the fastest growth during the forecast period 2020-2025, owing to the government initiates to treat cancer and increased health care expenditure. The Asia-Pacific region is also set to have healthy growth owing to the increased population and increased chronic diseases. An Increase in public programs to minimize cancer and raise in demand for the cancer is making an increase of the tissue diagnostic market in the European region.
Drivers – Tissue Diagnostics Market
Increased cancer patients
The demand for tissue diagnostics is increasing owing to increase in the population and increasing in chronic diseases over worldwide, the need of the tissue diagnostic in the treatment of the breast cancer, prostate cancer, and other is boosting the market during the forecast period 2020-2025.
Talk to one of our sales representative about the full report by providing your details in the link below:
Challenges – Tissue Diagnostics Market
High cost of tissue diagnostics
The increased cost of the equipment for the tissue diagnostics and increased cost of treatment is challenging the market in the developing countries during the forecast period 2020-2025.
Tissue Diagnostics Industry outlook:
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Tissue Diagnostics Market. Key companies of this market are GE Healthcare, BioGenex, Histoline Laboratories, Abbott Laboratories, Thermo Fisher Scientific Inc., Cell Signaling Technology, Inc, Cellpath Ltd, Biomeriux, Danaher, Roche, Sakura Fientek Japan and others.
In January 2018, Rouche launched novel uPath enterprise software, which is used to reduce the work from time and image rendering time and provides a detailed analysis in digital pathology.
In July 2018, Sakura Finetek USA has announced the launch of 3 antibodies and an antibody cocktail for the Tissue-Tek Genie Advanced staining system.
Geographically, North America’s Tissue Diagnostics Market accounted for the highest revenue share in 2019 and it is poised to dominate during the forecast period 2020-2025 owing to the high demand and increased infrastructure for the tissue diagnostic.
Increased usage of tissue diagnostics in the hospitals for the monitoring, diagnosis and management of different stages of cancer, especially for cancer like breast cancer, prostate cancer and others.
Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Tissue Diagnostics Market report.
Increase in the adaption of latest technology of tissue diagnostic and increased research and development in tissue diagnosis is fueling the market during the forecast period 2020-2025.
Related Reports :
A. Cancer Diagnostics Market
B. Tissue Banking Market
About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to email@example.com to discuss more about our consulting services.